Saba Capital Management’s European Biotech Acquisition Corp. Class A Ordinary Shares EBAC Stock Holding History

Saba Capital Management’s Portfolio EBAC Stock Details EBAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-17,293	Closed	-$175K	–	941
2022 Q4	$175K	Hold	17,293	–	–	﹤0.01%	580
2022 Q3	$171K	Hold	17,293	–	–	﹤0.01%	731
2022 Q2	$169K	Buy	17,293 +600	+4%	+$5.87K	﹤0.01%	782
2022 Q1	$163K	Buy	+16,693	New	+$162K	﹤0.01%	761

Saba Capital Management's EBAC Position: Q1 2023 in Review

Saba Capital Management sold out of European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) in Q1 2023, closing a stake of 17,293 shares — an estimated $175K sold.

Saba Capital Management first reported a position in EBAC in Q1 2022 and held it in 4 quarters. The position peaked at $175K in Q4 2022. 0 funds tracked by Wall St. Rank hold EBAC as of Q1 2023.

Saba Capital Management reported no remaining European Biotech Acquisition Corp. Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Saba Capital Management sold 17,293 European Biotech Acquisition Corp. Class A Ordinary Shares shares in Q1 2023, an estimated $175K.
Saba Capital Management first reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 4 quarters.
Saba Capital Management's European Biotech Acquisition Corp. Class A Ordinary Shares position peaked at $175K in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Class A Ordinary Shares as of Q1 2023.

Based on Saba Capital Management's 13F filing for Q1 2023, filed 15 May 2023.